<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="pt-BR">
		<id>http://www.infosus.saude.sc.gov.br/index.php?action=history&amp;feed=atom&amp;title=Iloprosta</id>
		<title>Iloprosta - Histórico de revisão</title>
		<link rel="self" type="application/atom+xml" href="http://www.infosus.saude.sc.gov.br/index.php?action=history&amp;feed=atom&amp;title=Iloprosta"/>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Iloprosta&amp;action=history"/>
		<updated>2026-04-23T08:43:14Z</updated>
		<subtitle>Histórico de revisões para esta página neste wiki</subtitle>
		<generator>MediaWiki 1.28.0</generator>

	<entry>
		<id>http://infosus.saude.sc.gov.br/index.php?title=Iloprosta&amp;diff=69662&amp;oldid=prev</id>
		<title>Anonimo: /* Informações sobre o financiamento do medicamento */</title>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Iloprosta&amp;diff=69662&amp;oldid=prev"/>
				<updated>2025-10-20T20:55:29Z</updated>
		
		<summary type="html">&lt;p&gt;‎&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Informações sobre o financiamento do medicamento&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;tr style='vertical-align: top;' lang='pt-BR'&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;← Edição anterior&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;Edição das 20h55min de 20 de outubro de 2025&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l35&quot; &gt;Linha 35:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linha 35:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Informações sobre o financiamento do medicamento==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Informações sobre o financiamento do medicamento==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;span style=&amp;quot;color:red&amp;quot;&amp;gt;'''O medicamento &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Iloprosta &lt;/del&gt;pertence ao [https://www.gov.br/saude/pt-br/composicao/sctie/daf/componentes-da-assistencia-farmaceutica-no-sus/ceaf/grupos-de-medicamentos Grupo 1B] do Componente Especializado da Assistência Farmacêutica (CEAF).'''&amp;lt;/span&amp;gt; O financiamento dos medicamentos que compõem o grupo 1B é de responsabilidade exclusiva da União, mediante transferência de recursos financeiros para aquisição pelas Secretarias de Saúde dos Estados.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;span style=&amp;quot;color:red&amp;quot;&amp;gt;'''O medicamento &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;iloprosta &lt;/ins&gt;pertence ao [https://www.gov.br/saude/pt-br/composicao/sctie/daf/componentes-da-assistencia-farmaceutica-no-sus/ceaf/grupos-de-medicamentos Grupo 1B] do Componente Especializado da Assistência Farmacêutica (CEAF).'''&amp;lt;/span&amp;gt; O financiamento dos medicamentos que compõem o grupo 1B é de responsabilidade exclusiva da União, mediante transferência de recursos financeiros para aquisição pelas Secretarias de Saúde dos Estados.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;'''O Grupo 1 (1A e 1B) é constituído por medicamentos que representam elevado impacto financeiro para o Componente, por aqueles indicados para doenças mais complexas, para os casos de refratariedade ou intolerância a primeira e/ou segunda linha de tratamento e por aqueles que se incluem em ações de desenvolvimento produtivo no complexo industrial da saúde'''. &amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;'''O Grupo 1 (1A e 1B) é constituído por medicamentos que representam elevado impacto financeiro para o Componente, por aqueles indicados para doenças mais complexas, para os casos de refratariedade ou intolerância a primeira e/ou segunda linha de tratamento e por aqueles que se incluem em ações de desenvolvimento produtivo no complexo industrial da saúde'''. &amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Anonimo</name></author>	</entry>

	<entry>
		<id>http://infosus.saude.sc.gov.br/index.php?title=Iloprosta&amp;diff=65463&amp;oldid=prev</id>
		<title>Anonimo: /* Informações sobre o financiamento do medicamento */</title>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Iloprosta&amp;diff=65463&amp;oldid=prev"/>
				<updated>2025-04-29T12:17:41Z</updated>
		
		<summary type="html">&lt;p&gt;‎&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Informações sobre o financiamento do medicamento&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;tr style='vertical-align: top;' lang='pt-BR'&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;← Edição anterior&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;Edição das 12h17min de 29 de abril de 2025&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l35&quot; &gt;Linha 35:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linha 35:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Informações sobre o financiamento do medicamento==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Informações sobre o financiamento do medicamento==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;span style=&amp;quot;color:red&amp;quot;&amp;gt;'''O medicamento &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;[[&lt;/del&gt;Iloprosta&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;]] &lt;/del&gt;pertence ao [https://www.gov.br/saude/pt-br/composicao/sctie/daf/componentes-da-assistencia-farmaceutica-no-sus/ceaf/grupos-de-medicamentos Grupo 1B] do Componente Especializado da Assistência Farmacêutica (CEAF).'''&amp;lt;/span&amp;gt; O financiamento dos medicamentos que compõem o grupo 1B é de responsabilidade exclusiva da União, mediante transferência de recursos financeiros para aquisição pelas Secretarias de Saúde dos Estados.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;span style=&amp;quot;color:red&amp;quot;&amp;gt;'''O medicamento Iloprosta pertence ao [https://www.gov.br/saude/pt-br/composicao/sctie/daf/componentes-da-assistencia-farmaceutica-no-sus/ceaf/grupos-de-medicamentos Grupo 1B] do Componente Especializado da Assistência Farmacêutica (CEAF).'''&amp;lt;/span&amp;gt; O financiamento dos medicamentos que compõem o grupo 1B é de responsabilidade exclusiva da União, mediante transferência de recursos financeiros para aquisição pelas Secretarias de Saúde dos Estados.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;'''O Grupo 1 (1A e 1B) é constituído por medicamentos que representam elevado impacto financeiro para o Componente, por aqueles indicados para doenças mais complexas, para os casos de refratariedade ou intolerância a primeira e/ou segunda linha de tratamento e por aqueles que se incluem em ações de desenvolvimento produtivo no complexo industrial da saúde'''. &amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;'''O Grupo 1 (1A e 1B) é constituído por medicamentos que representam elevado impacto financeiro para o Componente, por aqueles indicados para doenças mais complexas, para os casos de refratariedade ou intolerância a primeira e/ou segunda linha de tratamento e por aqueles que se incluem em ações de desenvolvimento produtivo no complexo industrial da saúde'''. &amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Anonimo</name></author>	</entry>

	<entry>
		<id>http://infosus.saude.sc.gov.br/index.php?title=Iloprosta&amp;diff=64319&amp;oldid=prev</id>
		<title>Anonimo: Substituição de texto - &quot;==Referências==
&lt;references/&gt;
*'''As demais referências utilizadas para elaboração deste medicamento constam em forma de link no decorrer do texto.'''&quot; por &quot;==Referências==
&lt;references/&gt;
'''''As demais referências utilizadas para elaboração deste medicamento constam em forma de link no decorrer do texto.'''''
&quot;</title>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Iloprosta&amp;diff=64319&amp;oldid=prev"/>
				<updated>2025-03-25T19:24:27Z</updated>
		
		<summary type="html">&lt;p&gt;Substituição de texto - &amp;quot;==Referências== &amp;lt;references/&amp;gt; *&amp;#039;&amp;#039;&amp;#039;As demais referências utilizadas para elaboração deste medicamento constam em forma de link no decorrer do texto.&amp;#039;&amp;#039;&amp;#039;&amp;quot; por &amp;quot;==Referências== &amp;lt;references/&amp;gt; &amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;As demais referências utilizadas para elaboração deste medicamento constam em forma de link no decorrer do texto.&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039; &amp;quot;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;tr style='vertical-align: top;' lang='pt-BR'&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;← Edição anterior&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;Edição das 19h24min de 25 de março de 2025&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l46&quot; &gt;Linha 46:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linha 46:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Referências==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Referências==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;*&lt;/del&gt;'''As demais referências utilizadas para elaboração deste medicamento constam em forma de link no decorrer do texto.'''&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;''&lt;/ins&gt;'''As demais referências utilizadas para elaboração deste medicamento constam em forma de link no decorrer do texto.&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;''&lt;/ins&gt;'''&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Anonimo</name></author>	</entry>

	<entry>
		<id>http://infosus.saude.sc.gov.br/index.php?title=Iloprosta&amp;diff=60785&amp;oldid=prev</id>
		<title>Anonimo: Substituição de texto - &quot;[https://www.saude.sc.gov.br/index.php/documentos/informacoes-gerais/vigilancia-em-saude/assistencia-farmaceutica/componente-especializado-da-assistencia-farmaceutica-ceaf/relacao-estadual-de-medicamentos-do-ceaf/14317-relacao-estadual-de-medicamentos-do-ceaf/file Clique aqui] para verificar se o medicamento compõe a Relação Estadual de Medicamentos do CEAF/SC.&quot; por &quot;[https://www.saude.sc.gov.br/index.php/pt/servicos/assistencia-farmaceutica-diaf/componente-especializado-da-assistencia-farmaceutica-ceaf Clique aqui] para verificar se o medicamento compõe a Relação Estadual de Medicamentos do CEAF/SC.&quot;</title>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Iloprosta&amp;diff=60785&amp;oldid=prev"/>
				<updated>2025-01-16T17:34:31Z</updated>
		
		<summary type="html">&lt;p&gt;Substituição de texto - &amp;quot;[https://www.saude.sc.gov.br/index.php/documentos/informacoes-gerais/vigilancia-em-saude/assistencia-farmaceutica/componente-especializado-da-assistencia-farmaceutica-ceaf/relacao-estadual-de-medicamentos-do-ceaf/14317-relacao-estadual-de-medicamentos-do-ceaf/file Clique aqui] para verificar se o medicamento compõe a Relação Estadual de Medicamentos do CEAF/SC.&amp;quot; por &amp;quot;[https://www.saude.sc.gov.br/index.php/pt/servicos/assistencia-farmaceutica-diaf/componente-especializado-da-assistencia-farmaceutica-ceaf Clique aqui] para verificar se o medicamento compõe a Relação Estadual de Medicamentos do CEAF/SC.&amp;quot;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;tr style='vertical-align: top;' lang='pt-BR'&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;← Edição anterior&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;Edição das 17h34min de 16 de janeiro de 2025&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l27&quot; &gt;Linha 27:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linha 27:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Informações sobre o medicamento ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Informações sobre o medicamento ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;O medicamento [[iloprosta]] está padronizado pelo Ministério da Saúde para o tratamento da '''Hipertensão Pulmonar - CID10 I27.0, I27.2, I27.8''', por meio do [[Componente Especializado da Assistência Farmacêutica (CEAF)]], '''na apresentação de 10 mcg/mL (solução para nebulização),''' sendo necessário o preenchimento dos critérios de inclusão definidos pelo Protocolo Clínico e Diretrizes Terapêuticas – PCDT da doença. [https://www.saude.sc.gov.br/index.php/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;documentos&lt;/del&gt;/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;informacoes-gerais/vigilancia-em-saude&lt;/del&gt;/assistencia-farmaceutica/componente-especializado-da-assistencia-farmaceutica-ceaf&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;/relacao-estadual-de-medicamentos-do-ceaf/14317-relacao-estadual-de-medicamentos-do-ceaf/file &lt;/del&gt;Clique aqui] para verificar se o medicamento compõe a Relação Estadual de Medicamentos do CEAF/SC.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;O medicamento [[iloprosta]] está padronizado pelo Ministério da Saúde para o tratamento da '''Hipertensão Pulmonar - CID10 I27.0, I27.2, I27.8''', por meio do [[Componente Especializado da Assistência Farmacêutica (CEAF)]], '''na apresentação de 10 mcg/mL (solução para nebulização),''' sendo necessário o preenchimento dos critérios de inclusão definidos pelo Protocolo Clínico e Diretrizes Terapêuticas – PCDT da doença. [https://www.saude.sc.gov.br/index.php/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;pt&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;servicos&lt;/ins&gt;/assistencia-farmaceutica&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;-diaf&lt;/ins&gt;/componente-especializado-da-assistencia-farmaceutica-ceaf Clique aqui] para verificar se o medicamento compõe a Relação Estadual de Medicamentos do CEAF/SC.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Para consultar quais documentos deverão ser apresentados para as solicitações de medicamentos do CEAF clique em [[Acesso ao Componente Especializado da Assistência Farmacêutica - CEAF]].&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Para consultar quais documentos deverão ser apresentados para as solicitações de medicamentos do CEAF clique em [[Acesso ao Componente Especializado da Assistência Farmacêutica - CEAF]].&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Anonimo</name></author>	</entry>

	<entry>
		<id>http://infosus.saude.sc.gov.br/index.php?title=Iloprosta&amp;diff=59323&amp;oldid=prev</id>
		<title>Anonimo: Substituição de texto - &quot;[https://www.gov.br/conitec/pt-br/midias/20220128_rename_2022.pdf Relação Nacional de Medicamentos Essenciais - RENAME 2022]&quot; por &quot;[https://bvsms.saude.gov.br/bvs/publicacoes/relacao_nacional_medicamentos_2024.pdf Relação Nacional de Medicamentos Essenciais - RENAME 2024]&quot;</title>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Iloprosta&amp;diff=59323&amp;oldid=prev"/>
				<updated>2025-01-14T13:19:50Z</updated>
		
		<summary type="html">&lt;p&gt;Substituição de texto - &amp;quot;[https://www.gov.br/conitec/pt-br/midias/20220128_rename_2022.pdf Relação Nacional de Medicamentos Essenciais - RENAME 2022]&amp;quot; por &amp;quot;[https://bvsms.saude.gov.br/bvs/publicacoes/relacao_nacional_medicamentos_2024.pdf Relação Nacional de Medicamentos Essenciais - RENAME 2024]&amp;quot;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;tr style='vertical-align: top;' lang='pt-BR'&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;← Edição anterior&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;Edição das 13h19min de 14 de janeiro de 2025&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l21&quot; &gt;Linha 21:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linha 21:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Padronização no SUS ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Padronização no SUS ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[https://&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;www&lt;/del&gt;.gov.br/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;conitec/pt-br&lt;/del&gt;/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;midias&lt;/del&gt;/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;20220128_rename_2022&lt;/del&gt;.pdf Relação Nacional de Medicamentos Essenciais - RENAME &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;2022&lt;/del&gt;]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[https://&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;bvsms.saude&lt;/ins&gt;.gov.br/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;bvs&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;publicacoes&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;relacao_nacional_medicamentos_2024&lt;/ins&gt;.pdf Relação Nacional de Medicamentos Essenciais - RENAME &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;2024&lt;/ins&gt;]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[https://www.gov.br/conitec/pt-br/midias/relatorios/portaria/2023/20230721_PORTARIAConjunta__DOU_10.pdf Portaria SAES/SECTICS/MS nº 10, de 18 de julho de 2023] - [https://www.gov.br/conitec/pt-br/midias/protocolos/portariaconjuntano10pcdthipertensaopulmonar.pdf Protocolo Clínico Diretrizes Terapêuticas da Hipertensão Pulmonar]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[https://www.gov.br/conitec/pt-br/midias/relatorios/portaria/2023/20230721_PORTARIAConjunta__DOU_10.pdf Portaria SAES/SECTICS/MS nº 10, de 18 de julho de 2023] - [https://www.gov.br/conitec/pt-br/midias/protocolos/portariaconjuntano10pcdthipertensaopulmonar.pdf Protocolo Clínico Diretrizes Terapêuticas da Hipertensão Pulmonar]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Anonimo</name></author>	</entry>

	<entry>
		<id>http://infosus.saude.sc.gov.br/index.php?title=Iloprosta&amp;diff=56282&amp;oldid=prev</id>
		<title>Anonimo: /* Informações sobre o financiamento do medicamento */</title>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Iloprosta&amp;diff=56282&amp;oldid=prev"/>
				<updated>2024-10-15T15:16:57Z</updated>
		
		<summary type="html">&lt;p&gt;‎&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Informações sobre o financiamento do medicamento&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;tr style='vertical-align: top;' lang='pt-BR'&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;← Edição anterior&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;Edição das 15h16min de 15 de outubro de 2024&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l40&quot; &gt;Linha 40:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linha 40:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;A responsabilidade pelo armazenamento, distribuição e dispensação dos medicamentos do Grupo 1 (1A e 1B) é das Secretarias Estaduais de Saúde. Independentemente do Grupo, o fornecimento de medicamentos padronizados no CEAF deve obedecer aos critérios de diagnóstico, indicação de tratamento, inclusão e exclusão de pacientes, esquemas terapêuticos, monitoramento, acompanhamento e demais parâmetros contidos nos Protocolos Clínicos e Diretrizes Terapêuticas (PCDT), estabelecidos pelo Ministério da Saúde, de abrangência nacional &amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;A responsabilidade pelo armazenamento, distribuição e dispensação dos medicamentos do Grupo 1 (1A e 1B) é das Secretarias Estaduais de Saúde. Independentemente do Grupo, o fornecimento de medicamentos padronizados no CEAF deve obedecer aos critérios de diagnóstico, indicação de tratamento, inclusão e exclusão de pacientes, esquemas terapêuticos, monitoramento, acompanhamento e demais parâmetros contidos nos Protocolos Clínicos e Diretrizes Terapêuticas (PCDT), estabelecidos pelo Ministério da Saúde, de abrangência nacional &amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;ref&amp;gt;[https://www.gov.br/saude/pt-br/composicao/sctie/daf/ceaf Componente Especializado da Assistência Farmacêutica] &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Acesso em 19/05/2023.&lt;/del&gt;&amp;lt;/ref&amp;gt;.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;ref&amp;gt;[https://www.gov.br/saude/pt-br/composicao/sctie/daf/ceaf Componente Especializado da Assistência Farmacêutica]&amp;lt;/ref&amp;gt;.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;span style=&amp;quot;color:blue&amp;quot;&amp;gt;'''Para mais informações sobre o financiamento e fornecimento dos medicamentos do Componente Especializado da Assistência Farmacêutica (CEAF) [[Componente Especializado da Assistência Farmacêutica (CEAF)|clique aqui]]'''&amp;lt;/span&amp;gt;.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;span style=&amp;quot;color:blue&amp;quot;&amp;gt;'''Para mais informações sobre o financiamento e fornecimento dos medicamentos do Componente Especializado da Assistência Farmacêutica (CEAF) [[Componente Especializado da Assistência Farmacêutica (CEAF)|clique aqui]]'''&amp;lt;/span&amp;gt;.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Anonimo</name></author>	</entry>

	<entry>
		<id>http://infosus.saude.sc.gov.br/index.php?title=Iloprosta&amp;diff=56281&amp;oldid=prev</id>
		<title>Anonimo: /* Indicações */</title>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Iloprosta&amp;diff=56281&amp;oldid=prev"/>
				<updated>2024-10-15T15:05:10Z</updated>
		
		<summary type="html">&lt;p&gt;‎&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Indicações&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;tr style='vertical-align: top;' lang='pt-BR'&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;← Edição anterior&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;Edição das 15h05min de 15 de outubro de 2024&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l17&quot; &gt;Linha 17:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linha 17:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Indicações ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Indicações ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;O medicamento '''iloprosta''' é indicado para o tratamento de hipertensão arterial pulmonar (grupo I OMS) em pacientes com sintomas classe funcional III ou IV (NYHA) &amp;lt;ref&amp;gt;[https://consultas.anvisa.gov.br/#/bulario/q/?numeroRegistro=170560076 Bula do medicamento Ventavis ® - Bula do profissional] &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Acesso em 19/05/2023.&lt;/del&gt;&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;O medicamento '''iloprosta''' é indicado para o tratamento de hipertensão arterial pulmonar (grupo I OMS) em pacientes com sintomas classe funcional III ou IV (NYHA) &amp;lt;ref&amp;gt;[https://consultas.anvisa.gov.br/#/bulario/q/?numeroRegistro=170560076 Bula do medicamento Ventavis ® - Bula do profissional] &amp;lt;/ref&amp;gt;&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;.&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Padronização no SUS ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Padronização no SUS ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Anonimo</name></author>	</entry>

	<entry>
		<id>http://infosus.saude.sc.gov.br/index.php?title=Iloprosta&amp;diff=56280&amp;oldid=prev</id>
		<title>Anonimo: /* Classificação Anatômica Terapêutica Química (ATC) */</title>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Iloprosta&amp;diff=56280&amp;oldid=prev"/>
				<updated>2024-10-15T15:04:13Z</updated>
		
		<summary type="html">&lt;p&gt;‎&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Classificação Anatômica Terapêutica Química (ATC)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;tr style='vertical-align: top;' lang='pt-BR'&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;← Edição anterior&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;Edição das 15h04min de 15 de outubro de 2024&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l9&quot; &gt;Linha 9:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linha 9:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Classificação Anatômica Terapêutica Química (ATC) ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Classificação Anatômica Terapêutica Química (ATC) ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Agente antitrombótico &amp;lt;ref&amp;gt;[https://&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;www&lt;/del&gt;.&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;whocc&lt;/del&gt;.no/atc_ddd_index/?code=B01&amp;amp;showdescription=no Grupo ATC] &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Acesso em 19/05/2023.&lt;/del&gt;&amp;lt;/ref&amp;gt; - B01AC11 &amp;lt;ref&amp;gt;[https://&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;www&lt;/del&gt;.&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;whocc&lt;/del&gt;.no/atc_ddd_index/?code=B01AC11 Código ATC] &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Acesso em 19/05/2023.&lt;/del&gt;&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Agente antitrombótico &amp;lt;ref&amp;gt;[https://&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;atcddd&lt;/ins&gt;.&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;fhi&lt;/ins&gt;.no/atc_ddd_index/?code=B01&amp;amp;showdescription=no Grupo ATC] &amp;lt;/ref&amp;gt; - B01AC11 &amp;lt;ref&amp;gt;[https://&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;atcddd&lt;/ins&gt;.&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;fhi&lt;/ins&gt;.no/atc_ddd_index/?code=B01AC11 Código ATC] &amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Nomes comerciais ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Nomes comerciais ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Anonimo</name></author>	</entry>

	<entry>
		<id>http://infosus.saude.sc.gov.br/index.php?title=Iloprosta&amp;diff=56279&amp;oldid=prev</id>
		<title>Anonimo: /* Registro na Anvisa */</title>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Iloprosta&amp;diff=56279&amp;oldid=prev"/>
				<updated>2024-10-15T15:03:29Z</updated>
		
		<summary type="html">&lt;p&gt;‎&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Registro na Anvisa&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;tr style='vertical-align: top;' lang='pt-BR'&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;← Edição anterior&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;Edição das 15h03min de 15 de outubro de 2024&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l5&quot; &gt;Linha 5:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linha 5:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;'''Categoria:''' medicamento&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;'''Categoria:''' medicamento&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;'''Classe terapêutica:''' &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Prostaglandinas &lt;/del&gt;&amp;lt;ref&amp;gt;[https://consultas.anvisa.gov.br/#/medicamentos/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;25351354083201031/&lt;/del&gt;?substancia=5474 Classe terapêutica do medicamento Ventavis ® - Registro ANVISA] &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Acesso em 19/05/2023.&lt;/del&gt;&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;'''Classe terapêutica:''' &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;prostaglandinas &lt;/ins&gt;&amp;lt;ref&amp;gt;[https://consultas.anvisa.gov.br/#/medicamentos/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;716425&lt;/ins&gt;?substancia=5474&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;&amp;amp;situacaoRegistro=V &lt;/ins&gt;Classe terapêutica do medicamento Ventavis ® - Registro ANVISA] &amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Classificação Anatômica Terapêutica Química (ATC) ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Classificação Anatômica Terapêutica Química (ATC) ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Anonimo</name></author>	</entry>

	<entry>
		<id>http://infosus.saude.sc.gov.br/index.php?title=Iloprosta&amp;diff=49890&amp;oldid=prev</id>
		<title>Anonimo: /* Informações sobre o medicamento */</title>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Iloprosta&amp;diff=49890&amp;oldid=prev"/>
				<updated>2023-07-25T17:03:26Z</updated>
		
		<summary type="html">&lt;p&gt;‎&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Informações sobre o medicamento&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;tr style='vertical-align: top;' lang='pt-BR'&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;← Edição anterior&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;Edição das 17h03min de 25 de julho de 2023&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l27&quot; &gt;Linha 27:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linha 27:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Informações sobre o medicamento ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Informações sobre o medicamento ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;O medicamento [[iloprosta]] está padronizado pelo Ministério da Saúde para o tratamento da '''Hipertensão &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Arterial &lt;/del&gt;Pulmonar - CID10 I27.0, I27.2, I27.8''', por meio do [[Componente Especializado da Assistência Farmacêutica (CEAF)]], '''na apresentação de 10 mcg/mL (solução para nebulização),''' sendo necessário o preenchimento dos critérios de inclusão definidos pelo Protocolo Clínico e Diretrizes Terapêuticas – PCDT da doença. [https://www.saude.sc.gov.br/index.php/documentos/informacoes-gerais/vigilancia-em-saude/assistencia-farmaceutica/componente-especializado-da-assistencia-farmaceutica-ceaf/relacao-estadual-de-medicamentos-do-ceaf/14317-relacao-estadual-de-medicamentos-do-ceaf/file Clique aqui] para verificar se o medicamento compõe a Relação Estadual de Medicamentos do CEAF/SC.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;O medicamento [[iloprosta]] está padronizado pelo Ministério da Saúde para o tratamento da '''Hipertensão Pulmonar - CID10 I27.0, I27.2, I27.8''', por meio do [[Componente Especializado da Assistência Farmacêutica (CEAF)]], '''na apresentação de 10 mcg/mL (solução para nebulização),''' sendo necessário o preenchimento dos critérios de inclusão definidos pelo Protocolo Clínico e Diretrizes Terapêuticas – PCDT da doença. [https://www.saude.sc.gov.br/index.php/documentos/informacoes-gerais/vigilancia-em-saude/assistencia-farmaceutica/componente-especializado-da-assistencia-farmaceutica-ceaf/relacao-estadual-de-medicamentos-do-ceaf/14317-relacao-estadual-de-medicamentos-do-ceaf/file Clique aqui] para verificar se o medicamento compõe a Relação Estadual de Medicamentos do CEAF/SC.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Para consultar quais documentos deverão ser apresentados para as solicitações de medicamentos do CEAF clique em [[Acesso ao Componente Especializado da Assistência Farmacêutica - CEAF]].&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Para consultar quais documentos deverão ser apresentados para as solicitações de medicamentos do CEAF clique em [[Acesso ao Componente Especializado da Assistência Farmacêutica - CEAF]].&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Anonimo</name></author>	</entry>

	</feed>